dennis mccain
  • Home
  • Investing
    • Dividend Kings
    • Div Aristocrats
    • Div Champions
    • Business Dev Cos
    • Monthly Dividends
  • Options
    • Weekly Options

Best Ideas This Week

These companies are estimated to have a very nice one year total return on investment.

Home

Best Ideas 30 September 2018

9/30/2018

0 Comments

 
Picture
Here's a couple of stock ideas I'm looking at for next week. These are companies I'll consider investing in with any funds that become available in my accounts. I believe each of these has a greater potential return than analysts currently expect. 

​As with all of my investments, I'll start with a small position and then add to that position over time through dividend reinvestment, the sale of stock options and direct purchases on the open market.
Picture
Weibo Corporation operates as a social media platform for people to create, distribute, and discover Chinese-language content. It operates through two segments, Advertising and Marketing Services, and Value-Added Services. The company offers self-expression products that enable its users to express themselves on its platform; social products to promote social interaction between users on its platform; and discovery products to help users discover content on its platform. It also provides third-party online games, including role-play, card, and strategy games, as well as various services and functions to VIP members. In addition, the company offers advertising and marketing solutions, such as social display advertisements; and promoted feeds, accounts, and trends enable its customers to promote their brands and conduct marketing activities. Further, it provides copyright content, such as TV channels, online video Websites, and operators with copyright content through traffic resource exchange and content traffic sharing; MCNs and other self-media to manage and provide services to content creators on Weibo, such as MCNs, unions, and e-commerce partners; other app developers an application platform which allows users to log into third-party applications; and Weibo Wallet products that enable platform partners to conduct interest generation activities on Weibo. The company was formerly known as T.CN Corporation and changed its name to Weibo Corporation in 2012. The company was founded in 2009 and is headquartered in Beijing, China. Weibo Corporation is a subsidiary of SINA Corporation.
(Summary) (Company) (Chart)
17 June 2018
Price $109.68
1yr Target $141.35
Analysts 20
Dividend $0.00
Payout Ratio 0.00%

1yr Cap Gain 28.87%
Yield 0.00%
1yr Tot Return 28.87%

P/E 61.17
PEG 1.28
Beta 2.49
​

EPS (ttm) $1.79
EPS next yr $4.03
Forward P/E 27.22
EPS next 5yr 47.88%
1yr Price Support $192.95

Market Cap $24.16 Bil
Revenues $1.30 Bil
Earnings $404.70 Mil
Profit Margin 31.13%

Quick Ratio 4.00
Current Ratio 4.00
Debt/Equity 0.66
​

1yr RevGR ---
3yr RevGR ---
5yr RevGR ---

1yr EarnGR ---
3yr EarnGR ---
5yr EarnGR ---

1yr DivGR ---
3yr DivGR ---
5yr DivGR ---

ROA 19.80%
ROE 36.20%
​

Cronos Group Inc., formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada's Marihuana for Medical Purposes Regulations (?MMPR?). The firm typically invests in companies based in Canada. The firm is primarily an equity investor, may also advance debt as appropriate. It seeks to make minority investments with appropriate governance and shareholder rights. The firm seeks board representation consistent with the size of the investment, but does not need control. Cronos Group Inc. was incorporated in January, 2013 and is based in Toronto, Canada with an additional office in in Toronto, Canada.
​(Summary) (Company) (Chart)
26 August 2018
Price $9.94
1yr Target ---
Analysts ---
Dividend ---
Payout Ratio ---

1yr Cap Gain ---
Yield ---
1yr Tot Return ---

EPS (ttm) $0.01
EPS next yr ---
Forward P/E ---
EPS next 5yr ---
1yr Price Support ---

Market Cap $1.32 Bil
Revenues $4.90 Mil
Earnings ---
Profit Margin ---

P/E 1656.67
PEG ---
Beta ---

Quick Ratio ---
Current Ratio ---
Debt/Equity ---

ROA ---
ROE ---

0 Comments

Best Ideas 23 September 2018

9/22/2018

0 Comments

 
Picture
Here's a couple of stock ideas I'm looking at for next week. These are companies I'll consider investing in with any funds that become available in my accounts. I believe each of these has a greater potential return than analysts currently expect. 

​As with all of my investments, I'll start with a small position and then add to that position over time through dividend reinvestment, the sale of stock options and direct purchases on the open market.
Picture
Cronos Group Inc., formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada's Marihuana for Medical Purposes Regulations (?MMPR?). The firm typically invests in companies based in Canada. The firm is primarily an equity investor, may also advance debt as appropriate. It seeks to make minority investments with appropriate governance and shareholder rights. The firm seeks board representation consistent with the size of the investment, but does not need control. Cronos Group Inc. was incorporated in January, 2013 and is based in Toronto, Canada with an additional office in in Toronto, Canada.
​(Summary) (Company) (Chart)
26 August 2018
Price $9.94
1yr Target ---
Analysts ---
Dividend ---
Payout Ratio ---

1yr Cap Gain ---
Yield ---
1yr Tot Return ---

​​
EPS (ttm) $0.01
EPS next yr ---
Forward P/E ---
EPS next 5yr ---
1yr Price Support ---

Market Cap $1.32 Bil
Revenues $4.90 Mil
Earnings ---
Profit Margin ---
​

P/E 1656.67
PEG ---
Beta ---

Quick Ratio ---
Current Ratio ---
Debt/Equity ---

ROA ---
ROE ---

0 Comments

Best Ideas 16 September 2018

9/16/2018

0 Comments

 
Picture
Here's a couple of stock ideas I'm looking at for next week. These are companies I'll consider investing in with any funds that become available in my accounts. I believe each of these has a greater potential return than analysts currently expect. 

​As with all of my investments, I'll start with a small position and then add to that position over time through dividend reinvestment, the sale of stock options and direct purchases on the open market.
Picture
General Electric Company operates as a digital industrial company worldwide. It operates through Power, Renewable Energy, Oil & Gas, Aviation, Healthcare, Transportation, Lighting, and Capital segments. The Power segment offers technologies, solutions, and services related to energy production, including gas and steam turbines, engines, generators, and high voltage equipment; and power generation services and digital solutions. The Renewable Energy segment provides wind turbine platforms, and hardware and software; offshore wind turbines; solutions, products, and services to hydropower industry; and blades for onshore and offshore wind turbines. The Oil & Gas segment offers oilfield services, oilfield equipment, turbomachinery and process solutions, and digital solutions. The Aviation segment provides jet engines and turboprops; maintenance, component repair, and overhaul services, as well as replacement parts; and additive machines, materials, and engineering services. The Healthcare segment offers diagnostic imaging and clinical systems; products, services, and manufacturing solutions for drug discovery, the biopharmaceutical industry, and cellular and gene therapy technologies; and medical technologies, software, analytics, cloud solutions, and implementation and services. The Transportation segment provides freight and passenger locomotives, and rail and support advisory services; parts, integrated software solutions, and data analytics; software-enabled solutions; mining equipment and services; and marine diesel and stationary power diesel engines and motors, as well as overhaul, repair and upgrade, and wreck repair services. The Lighting segment offers light emitting diode products; and energy efficiency and productivity solutions. The Capital segment provides industrial and energy financial services; and commercial aircraft leasing, financing, and consulting services. General Electric Company was founded in 1892 and is headquartered in Boston, Massachusetts.
(Summary) (Chart)
16 September 2018
Price $12.68
1yr Target $16.89
Analysts 14
Dividend $0.48
Payout Ratio ---

1yr Cap Gain 33.20%
Yield 3.78%
1yr Tot Return 36.98%
​
EPS (ttm) $-0.42
EPS next yr $1.01
Forward P/E 12.53
EPS next 5yr 6.17%
1yr Price Support $

Market Cap $110.46 Bil
Revenues $122.48 Bil
Earnings $-3.59 Mil
Profit Margin ---


P/E ---
PEG ---
Beta 0.96

Quick Ratio ---
Current Ratio ---
Debt/Equity 2.10

ROA -2.40%
ROE -14.20%
​
0 Comments

Best Ideas 26 Aug/2&9 September 2018

9/9/2018

0 Comments

 
Picture
Here's a couple of stock ideas I'm looking at for next week. These are companies I'll consider investing in with any funds that become available in my accounts. I believe each of these has a greater potential return than analysts currently expect. 

​As with all of my investments, I'll start with a small position and then add to that position over time through dividend reinvestment, the sale of stock options and direct purchases on the open market.
Picture
Canopy Growth Corporation engages in growing, possession, and sale of medical cannabis in Canada. Its products include dried flowers, oils and concentrates, softgel capsules, and hemps. The company offers its products under the Tweed, Black Label, Spectrum Cannabis, DNA Genetics, Leafs By Snoop, Bedrocan Canada, CraftGrow, and Foria brand names. It also offers its products through Tweed Main Street, a single online platform that enables registered patients to purchase medicinal cannabis from various producers across various brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation is headquartered in Smiths Falls, Canada.
(Summary) Company) (Chart)
26 August 2018
Price $45.00
1yr Target $---
Analysts ---
Dividend ---
Payout Ratio ---

1yr Cap Gain ---
Yield ---
1yr Tot Return ---
​
EPS (ttm) $-0.30
EPS next yr ---
Forward P/E ---
EPS next 5yr ---
1yr Price Support ---

Market Cap $7.55 Bil
Revenues $58.60 Mil
Earnings ---
Profit Margin ---


P/E ---
PEG ---
Beta ---

Quick Ratio ---
Current Ratio ---
Debt/Equity ---

ROA ---
ROE ---
​
Cronos Group Inc., formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada's Marihuana for Medical Purposes Regulations (?MMPR?). The firm typically invests in companies based in Canada. The firm is primarily an equity investor, may also advance debt as appropriate. It seeks to make minority investments with appropriate governance and shareholder rights. The firm seeks board representation consistent with the size of the investment, but does not need control. Cronos Group Inc. was incorporated in January, 2013 and is based in Toronto, Canada with an additional office in in Toronto, Canada.
​(Summary) (Company) (Chart)
26 August 2018
Price $9.94
1yr Target ---
Analysts ---
Dividend ---
Payout Ratio ---

1yr Cap Gain ---
Yield ---
1yr Tot Return ---

​
EPS (ttm) $0.01
EPS next yr ---
Forward P/E ---
EPS next 5yr ---
1yr Price Support ---

Market Cap $1.32 Bil
Revenues $4.90 Mil
Earnings ---
Profit Margin ---
​
P/E 1656.67
PEG ---
Beta ---

Quick Ratio ---
Current Ratio ---
Debt/Equity ---

ROA ---
ROE ---
​
Tilray Inc is engaged in sale and development of medical cannabis. Geographically, the company derives majority of its revenue from Canada. The product categories of the company include dried cannabis which include whole flower and ground flower,and cannabis extract which include full spectrum and purified oil drops and capsules.
​(Summary) (Company) (Chart)
26 August 2018
Price $43.86
1yr Target $34.67
Analysts 3
Dividend ---
Payout Ratio ---

1yr Cap Gain ---
Yield ---
1yr Tot Return ---

​
EPS (ttm) $-0.13
EPS next yr $0.05
Forward P/E 877.20
EPS next 5yr ---
1yr Price Support ---

Market Cap $3.82 Bil
Revenues $23.30 Mil
Earnings $-12.30 Mil
Profit Margin ---
​
P/E ---
PEG ---
Beta ---

Quick Ratio 0.80
Current Ratio 1.00
Debt/Equity 1.23

ROA ---
ROE ---
​
GW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. The company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. Its lead product is Epidiolex, an oral medicine which is in Phase III clinical development for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms. The company also develops and markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates, which are in Phase I and II clinical development for the treatment of glioma, neonatal hypoxic-ischemic encephalopathy, adult epilepsy, and schizophrenia. Further, the company has license and development agreements with Otsuka Pharmaceutical Co. Ltd.; Almirall S.A.; Bayer HealthCare AG; Ipsen Biopharm Ltd; and Neopharm Group. It primarily operates in Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.
​(Summary) (Company) (Chart)
26 August 2018
Price $143.29
1yr Target $169.00
Analysts 8
Dividend ---
Payout Ratio ---

1yr Cap Gain 17.94%
Yield ---
1yr Tot Return 17.94%

​
EPS (ttm) $-9.23
EPS next yr $-4.49
Forward P/E ---
EPS next 5yr ---
1yr Price Support ---

Market Cap $3.88 Bil
Revenues $16.10 Bil
Earnings $-243.30 Mil
Profit Margin ---
​
P/E ---
PEG ---
Beta 2.80

Quick Ratio 11.20
Current Ratio 11.30
Debt/Equity 0.01

ROA -46.10%
ROE -52.70%
​
0 Comments
    Picture
    Dennis McCain

    Author

    I am an Individual Investor with specific interest in long term growth and then enhancing my returns with income from dividends and derivatives. I don't recommend stocks to anyone (it's a good way to lose friends) and no one reading this should misinterpret my blog as a recommendation for any type of investment. I am writing this solely for myself and my kids.

    Picture
    Top 100 Blogs for Dividend Investors

    Archives

    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    July 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    July 2017
    June 2017
    May 2017
    April 2017
    March 2017
    February 2017
    January 2017
    December 2016
    November 2016
    October 2016
    September 2016
    August 2016
    July 2016
    June 2016
    May 2016
    April 2016
    March 2016
    February 2016
    January 2016
    December 2015
    November 2015
    October 2015
    September 2015
    August 2015
    July 2015
    June 2015
    May 2015
    April 2015
    March 2015
    February 2015
    January 2015
    December 2014
    November 2014

    DISCLAIMER
     I am not a licensed investment adviser, and I am not providing investment advise for you on this site. Please consult with an investment professional before you invest your money. Any opinion expressed here should not be treated as investment advice. I am not liable for any losses suffered by any party because of data or information published on this blog. Past performance is not a guarantee of future performance. Unless your investments are FDIC insured, they may decline in value.

    Categories

    All

    RSS Feed

Powered by Create your own unique website with customizable templates.